Breaking News
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

Anthera Pharma Halts Vista-16 Trial; Stock Down 55% - Update

3/9/2012 7:31 PM ET

Shares of Anthera Pharmaceuticals Inc. (ANTH: Quote) plummeted 55 percent in after-hours trade Friday, after the company said it halted the Phase 3 clinical study of its heart drug varespladib methyl.

The Phase 3 study, Vista-16, is an event driven trial evaluating varespladib methyl in combination with Lipitor to reduce secondary Major Adverse Cardiovascular Events in patients who recently experienced an Acute Coronary Syndrome, or ACS - a disease involving the coronary arteries.

Anthera's decision to abandon the Vista-16 study was based on a recommendation by the VISTA-16 Data Safety Monitoring Board, which cited lack of efficacy that could not be overcome in the remainder of the trial.

Anthera said it has closed enrollment in the phase 3 VISTA-16 study and informed investigators to remove patients from therapy.

Varespladib is a potent oral inhibitor of a number of pro-inflammatory enzymes collectively known as secretory phospholipase A2, or sPLA2.

Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including ACS, and are associated with an increased risk for future ischemic events, such as a heart attack or even death.

Anthera has worldwide product rights to varespladib, except in Japan where Shionogi & Co., Ltd. retains rights.

The late stage study of varespladib was commenced last June. The study was designed to enroll 6,500 high-risk acute coronary syndrome patients across 15 countries.

The primary endpoint of the study pertained to a reduction in major adverse coronary events like cardiovascular death, non-fatal myocardial infarction, non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring hospitalization.

Anthera is a development-stage company, and to date, has not generated any revenue. In the recent fourth quarter, its net loss widened to $29.2 million or $0.71 per share from a loss of $13.0 million or $0.40 per share last year.

The company's pipeline includes A-623. The study, PEARL-SC, is examining the therapeutic benefit of weekly and monthly subcutaneous injections of blisibimod in patients with active and antibody positive systemic lupus erythematosus.

Anthera recently said it would continue the Phase 2b PEARL-SC clinical study. The company expects top-line efficacy data from the PEARL-SC clinical study in the second quarter 2012.

Anthera's third product candidate is A-001, which has completed a phase II clinical study for the prevention of acute chest syndrome associated with sickle cell disease.

Anthera went public in March 2010, offering its shares at a price of $7.00 each. Anthera shares closed Friday on the Nasdaq at $6.42, up $0.28 or 4.56%. In after hours, the stock dropped $3.55 or 55.30%.

Register
To receive FREE breaking news email alerts for Anthera Pharmaceuticals, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Israel on Thursday announced it has suspended the US-mediated peace talks with the Palestinians in response to a unity accord reached between the two rival Palestinian groups, the Hamas and the Fatah. The development comes just a day after the Hamas, a radical Islamist group that controls Gaza, and the Fatah faction that rules the West Bank announced a reconciliation deal. The two groups said they While U.S. President Barack Obama and his Russian counterpart Vladimir Putin have called for a diplomatic solution to the ongoing crisis in Ukraine, the two leaders both made comments Thursday with the potential to inflame rather than tamp down the situation. After initially showing a lack of direction, stocks have moved mostly higher over the course of the trading day on Thursday. The strength that has emerged on the day has largely offset the weakness that was seen in the previous session. The major averages have moved roughly sideways in recent trading, hovering in positive territory.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.